Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Clinical Success Rate
    100.0%

    Based on 1 completed trials

    Completion Rate
    100%(1/1)
    Active Trials
    1(33%)
    Results Posted
    0%(0 trials)

    Phase Distribution

    Phase 2
    1
    33%
    Phase 2/3
    1
    33%
    Not Applicable
    1
    33%

    Phase Distribution

    0

    Early Stage

    2

    Mid Stage

    0

    Late Stage

    Phase Distribution3 total trials
    Phase 2Efficacy & side effects
    1(33.3%)
    Phase 2/3Combined phases
    1(33.3%)
    N/ANon-phased studies
    1(33.3%)

    Highest Phase Reached

    Phase 2/3

    Trial Status & Enrollment

    Completion Rate

    50.0%

    1 of 2 finished

    Non-Completion Rate

    50.0%

    1 ended early

    Currently Active

    1

    trials recruiting

    Total Trials

    3

    all time

    Status Distribution
    Active(1)
    Completed(1)
    Terminated(1)

    Detailed Status

    Active, not recruiting1
    Completed1
    Withdrawn1

    Development Timeline

    Analytics

    Development Status

    Total Trials
    3
    Active
    1
    Success Rate
    100.0%
    Most Advanced
    Phase 2/3

    Trials by Phase

    Phase 21 (33.3%)
    Phase 2/31 (33.3%)
    N/A1 (33.3%)

    Trials by Status

    active_not_recruiting133%
    completed133%
    withdrawn133%

    Recent Activity

    1 active trials
    Showing 3 of 3
    active_not_recruitingphase_2_3

    Feasibility Study of MET-4: Evaluating Fecal Microbiome Effects in Immunotherapy Patients

    NCT03686202
    completednot_applicable

    Role of Microbiome as a Biomarkers in Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma 2

    NCT03838601
    withdrawnphase_2

    PembROlizumab With or Without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma

    NCT05743777

    Clinical Trials (3)

    Showing 3 of 3 trials
    NCT03686202Phase 2/3

    Feasibility Study of MET-4: Evaluating Fecal Microbiome Effects in Immunotherapy Patients

    Active Not Recruiting
    NCT03838601Not Applicable

    Role of Microbiome as a Biomarkers in Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma 2

    Completed
    NCT05743777Phase 2

    PembROlizumab With or Without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma

    Withdrawn

    All 3 trials loaded

    Drug Details

    Intervention Type
    Varies by study
    Total Trials
    3